ArticleBMJ open2026

Neoadjuvant/adjuvant relugolix and enzalutamide for the treatment of high-risk locally advanced prostate cancer: study protocol of the RENAPCA phase Ib trial.

Matthew Loper et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.